JANX241220P60000
- 1.49
- -2.91-66.14%
Janux Therapeutics Newsroom
Scotiabank Maintains Sector Perform on Janux Therapeutics, Raises Price Target to $62
Janux Therapeutics Price Target Raised to $91.00/Share From $79.00 by Leerink Partners
Janux Therapeutics Is Maintained at Outperform by Leerink Partners
Scotiabank Raises Price Target on Janux Therapeutics to $62 From $42, Keeps Sector Perform Rating
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Raises Target Price to $70
HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Raises Price Target to $70
Janux Therapeutics Analyst Ratings
Buy Rating Affirmed for Janux Therapeutics Inc. Amid Promising Clinical Data and Strategic Advancements
Janux Therapeutics Initiated at Outperform by Leerink Partners
Leerink Partners Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $79
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), 89bio (ETNB) and Ardent Health Partners, Inc. (ARDT)
Janux Therapeutics Analyst Ratings
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70
Cantor Fitzgerald Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100
TD Cowen Maintains Janux Therapeutics(JANX.US) With Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: CVS Health (CVS), Amicus (FOLD) and Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc (JANX) Receives a Buy From Cantor Fitzgerald
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $63
Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position